348 related articles for article (PubMed ID: 29599409)
1. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
[No Abstract] [Full Text] [Related]
2. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
[TBL] [Abstract][Full Text] [Related]
3. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.
Choonoo G; Blucher AS; Higgins S; Boardman M; Jeng S; Zheng C; Jacobs J; Anderson A; Chamberlin S; Evans N; Vigoda M; Cordier B; Tyner JW; Kulesz-Martin M; McWeeney SK; Laderas T
PLoS One; 2019; 14(10):e0223639. PubMed ID: 31596908
[TBL] [Abstract][Full Text] [Related]
4. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
6. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
7. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
8. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.
van Harten AM; de Boer DV; Martens-de Kemp SR; Buijze M; Ganzevles SH; Hunter KD; Leemans CR; van Beusechem VW; Wolthuis RMF; de Menezes RX; Brakenhoff RH
Sci Rep; 2020 Feb; 10(1):2330. PubMed ID: 32047167
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
11. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
[TBL] [Abstract][Full Text] [Related]
12. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
13. Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.
Lepikhova T; Karhemo PR; Louhimo R; Yadav B; Murumägi A; Kulesskiy E; Kivento M; Sihto H; Grénman R; Syrjänen SM; Kallioniemi O; Aittokallio T; Wennerberg K; Joensuu H; Monni O
Mol Cancer Ther; 2018 Sep; 17(9):2060-2071. PubMed ID: 29970484
[TBL] [Abstract][Full Text] [Related]
14. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.
Giefing M; Wierzbicka M; Szyfter K; Brenner JC; Braakhuis BJ; Brakenhoff RH; Bradford CR; Sorensen JA; Rinaldo A; Rodrigo JP; Takes RP; Ferlito A
Eur J Cancer; 2016 Mar; 55():147-57. PubMed ID: 26851381
[TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
16. Genomic sequencing and precision medicine in head and neck cancers.
Hoesli RC; Ludwig ML; Michmerhuizen NL; Rosko AJ; Spector ME; Brenner JC; Birkeland AC
Eur J Surg Oncol; 2017 May; 43(5):884-892. PubMed ID: 28034498
[TBL] [Abstract][Full Text] [Related]
17. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
18. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
